This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldstein, D. Articles by Borden, E. C. Search for Related Content PubMed PubMed Citation Articles by Goldstein, D. Articles by Borden, E. C.

Effects of Type I and II Interferons on Cultured Human Breast Cells: Interaction with Estrogen Receptors and with Tamoxifen¹

Department of Human Oncology, University of Wisconsin Cancer Center, Madison, Wisconsin 53792

The combined effects of tamoxifen, a competitive inhibitor of estrogen, and type I or II interferons on the proliferation of several human breast cancer cell lines in vitro were examined. Additive antiproliferative effects were observed with interferons and tamoxifen, in two estrogen receptor positive cell lines, MCF-7 and T-47D. In MCF-7 cells neither ßser interferon, interferon, nor 6 interferon were able to significantly alter estrogen receptor levels. Antigrowth activities of ßser interferon and interferon in an estrogen receptor negative cell line, HS578T, were equivalent to those in estrogen receptor-positive cell lines. Consistent with the antiproliferative effects of interferons, high affinity ßser interferon receptors and interferon inducible 2'5'-oligoadenylate synthetase were present in both MCF-7 and HS578T cell lines. Thus steroid hormone receptor status did not influence the antiproliferative effects of interferons on breast carcinoma cells in vitro.

¹ Supported in part by Triton Biosciences and NIH/NCI CA 20432.

² To whom requests for reprints should be addressed, at K4/410 Department of Human Oncology, University of Wisconsin, Clinical Science Center, 600 Highland Avenue, Madison, WI 53792.

³ American Cancer Society Professor of Clinical Oncology.

Received 10/21/88. Revised 2/16/89. Accepted 2/21/89.

This article has been cited by other articles:

				F. Morgillo, W.-Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong, and H.-Y. Lee Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib Clin. Cancer Res., May 1, 2007; 13(9): 2795 - 2803. [Abstract] [Full Text] [PDF]

				F. Morgillo, J. K. Woo, E. S. Kim, W. K. Hong, and H.-Y. Lee Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib. Cancer Res., October 15, 2006; 66(20): 10100 - 10111. [Abstract] [Full Text] [PDF]